AT1 FY21 - General Discussion + FA, page-1796

they key for me is they GIFTED AccessBio $5mill (AUD); the take or pay should have netted $7mill+ (not in revenue but in operating profit); when they negotiated a $2.4 mill break fee (when it should have been over $7mill) it leads me to some concern in their business sense; now one can 'guess' the guaranteed supply and pricing of the antigen tests (the 20 mill) may recoup that; but who knows; and if we dont happen to sell 20 mill, well, then for sure, you have simply punted $5mill of shareholders funds

now compare the size of AccessBio and Atomo and I am concerned maybe we rolled over

I am hanging in with my last week parcel of shares on the hope there is a spike between now and Jan; spike would be actual sales of the antigen test and the FebriDx approval (mind you, Lumos have changed their tune to 'we hope it will get approved in FY22' - that is pushed back 6 to 9 months

by Jan, the price of Atomo may be back to 20 cents or it may be 45 cents; with no news it will bleed to 20; but with good news it will jump back up; but the company is not at all what I first invested in and I am hoping to exit at least above 30

overall I think the product is good, but the management (and contracts) are very poor